| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/10/2013 | EP2611802A1 Bicyclic aza heterocycles, and use thereof |
| 07/10/2013 | EP2611799A2 Pharmaceutical compositions of linezolid |
| 07/10/2013 | EP2611798A1 Pyridazinones, method of making, and method of use thereof |
| 07/10/2013 | EP2611797A2 Quinoline or quinazoline derivatives with apoptosis inducing activity on cells |
| 07/10/2013 | EP2611796A1 An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof |
| 07/10/2013 | EP2611795A1 An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof |
| 07/10/2013 | EP2611794A1 4-azolylaminoquinazoline derivatives and methods of use thereof |
| 07/10/2013 | EP2611793A1 2-cycloquinazoline derivatives and methods of use thereof |
| 07/10/2013 | EP2611792A1 Hydrobromide salts of a pyrazolylaminoquinazoline |
| 07/10/2013 | EP2611791A1 Oligooxopiperazines and methods of making and using them |
| 07/10/2013 | EP2611790A1 Pyridinones/pyrazinones, method of making, and method of use thereof |
| 07/10/2013 | EP2611789A1 Quinazoline compounds and methods of use thereof |
| 07/10/2013 | EP2611788A2 Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use |
| 07/10/2013 | EP2611783A2 Heterocyclic compounds as dgat1 inhibitors |
| 07/10/2013 | EP2611782A1 Salts of lorcaserin with optically active acids |
| 07/10/2013 | EP2611781A1 Fast-dissolve dosage forms of 5-ht2c agonists |
| 07/10/2013 | EP2611780A1 Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as kcnq2/3 modulators |
| 07/10/2013 | EP2611779A1 CRYSTALLINE FORMS OF A FACTOR Xa INHIBITOR |
| 07/10/2013 | EP2611778A1 Guanidine compounds and compositions for the inhibition of nampt |
| 07/10/2013 | EP2611777A1 4- { [ ( pyridin- 3 - yl -methyl) aminocarbonyl]amino} benzene - sulfone derivatives as nampt inhibitors for therapy of diseases such as cancer |
| 07/10/2013 | EP2611776A2 Production method of intermediate compound for synthesizing medicament |
| 07/10/2013 | EP2611774A1 Di-azetidinyl diamide as monoacylglycerol lipase inhibitors |
| 07/10/2013 | EP2611772A1 2 - (benzyloxy) benzamides as lrrk2 kinase inhibitors |
| 07/10/2013 | EP2611765A2 Methods for treating neurodegenerative diseases |
| 07/10/2013 | EP2611759A1 Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| 07/10/2013 | EP2611502A1 Adenosine a3 receptor modulating compounds and methods of use thereof |
| 07/10/2013 | EP2611453A1 Antifungal composition |
| 07/10/2013 | EP2611451A2 Design of oligonucleotide analogs as therapeutic agents |
| 07/10/2013 | EP2611450A1 Tyrosine kinase inhibitors |
| 07/10/2013 | EP2611449A1 Administration of lorcaserin to individuals with renal impairment |
| 07/10/2013 | EP2611448A1 7-cyclylquinazoline derivatives and methods of use thereof |
| 07/10/2013 | EP2611447A2 Formulation of comprising tiotropium and a calcium channel blocker |
| 07/10/2013 | EP2611446A1 Crystalline forms of maraviroc phosphate and process for maraviroc amorphous form |
| 07/10/2013 | EP2611445A1 High dose buprenorphine compositions and use as analgesic |
| 07/10/2013 | EP2611444A1 Heterocyclyl compounds as histamine h3 receptor ligands |
| 07/10/2013 | EP2611443A2 Methods for treatment of non-small cell lung cancer |
| 07/10/2013 | EP2611442A2 Drug formulations using water soluble antioxidants |
| 07/10/2013 | EP2611441A1 Bace inhibitors for use in the treatment of diabetes |
| 07/10/2013 | EP2611440A1 Treatment for cocaine addiction |
| 07/10/2013 | EP2611439A1 Composition comprising a combination of dha and epa for administration prior to commencement of chemotherapy |
| 07/10/2013 | EP2611438A1 Dry powder formulations and methods for treating pulmonary diseases |
| 07/10/2013 | EP2611437A1 Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis |
| 07/10/2013 | EP2611436A1 Combination of hdac inhibitors with thrombocytopenia drugs |
| 07/10/2013 | EP2611435A2 Controlled release pharmaceutical compositions of milnacipran |
| 07/10/2013 | EP2611434A1 Pharmaceutical composition comprising metformin and pioglitazone |
| 07/10/2013 | EP2611433A2 Non-hygroscopic salts of 5-ht2c agonists |
| 07/10/2013 | EP2611432A1 Rheumatoid arthritis treatment using polyunsaturated long chain ketones |
| 07/10/2013 | EP2611429A1 Mesalazine tablet having improved dissolution |
| 07/10/2013 | EP2611427A2 MODIFIED-RELEASE DOSAGE FORMS OF 5-HT2C AGONISTS USEFUL FOR WEIGHT MANAGEMENT& xA; |
| 07/10/2013 | EP2611423A1 Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
| 07/10/2013 | EP2611422A1 Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
| 07/10/2013 | EP2611415A1 Adenosine a1 agonists for the treatment of glaucoma and ocular hypertension |
| 07/10/2013 | EP2611413A2 Skin compositions and methods of use thereof |
| 07/10/2013 | EP2611313A1 Method and preparation for the treatment or prevention of anxiety or neurogenesis |
| 07/10/2013 | EP2611299A1 Pesticidal compositions |
| 07/10/2013 | EP2611298A1 Bicyclic oxazole and thiazole compounds and their use as allosteric modulators of mglur5 receptors |
| 07/10/2013 | EP2611295A1 Fused tricyclic ether carbamates and their use |
| 07/10/2013 | CN203043010U Nifedipine sustained-release tablet (II) |
| 07/10/2013 | CN1990473B Tri-substituted 1H-imidazoles compounds, preparation method and pharmaceutical composition and pharmacy use thereof |
| 07/10/2013 | CN1989254B Processes for producing cellooligosaccharide |
| 07/10/2013 | CN1956946B Modulators of cannabinoid receptors |
| 07/10/2013 | CN1809340B Pharmaceutical products |
| 07/10/2013 | CN103201387A Treatment of interferon-related developmental regulator 1 (IFRD1) related diseases by inhibition of natural antisense transcript to IFRD1 |
| 07/10/2013 | CN103201296A Novel photoinitiators |
| 07/10/2013 | CN103201280A Compositions and methods for inhibition of the jak pathway |
| 07/10/2013 | CN103201279A Compounds useful as modulators of TRPM8 |
| 07/10/2013 | CN103201277A Pyridazinones, method of making, and method of use thereof |
| 07/10/2013 | CN103201276A Indole derivatives |
| 07/10/2013 | CN103201275A Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
| 07/10/2013 | CN103201274A Pyrrolidine derivatives used as cathepsin inhibitors |
| 07/10/2013 | CN103201271A Derivatives of oxadiazole and pyridazine, their preparation and their application in therapeutics |
| 07/10/2013 | CN103201270A P2x4 receptor antagonist |
| 07/10/2013 | CN103201267A Ampk-activating heterocyclic compounds and methods for using the same |
| 07/10/2013 | CN103201263A P53-Mdm2 antagonists |
| 07/10/2013 | CN103201262A Autotaxin inhibitors and uses thereof |
| 07/10/2013 | CN103201261A Lactam derivatives useful as orexin receptor antagonists |
| 07/10/2013 | CN103201258A Amyloid binding agents |
| 07/10/2013 | CN103201257A Substituted amino bisphenyl pentanoic acid derivatives as nep inhibitors |
| 07/10/2013 | CN103200958A Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients |
| 07/10/2013 | CN103200949A Composition for treating neurodegenerative disease or neuropathological condition |
| 07/10/2013 | CN103200946A Compositions for treating chronic viral infections |
| 07/10/2013 | CN103200945A RNA interference in ocular indications |
| 07/10/2013 | CN103200944A Transdermal therapeutic system comprising buprenorphine |
| 07/10/2013 | CN103200943A Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members |
| 07/10/2013 | CN103200942A Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol |
| 07/10/2013 | CN103200941A Ester pro-drugs of [3-(1-(1h-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for lowering intraocular pressure |
| 07/10/2013 | CN103200940A Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines |
| 07/10/2013 | CN103200939A Composition comprising a combination of DHA and EPA for administration prior to commencement of chemotherapy |
| 07/10/2013 | CN103200938A Dry powder formulations and methods for treating pulmonary diseases |
| 07/10/2013 | CN103200937A Composition and method for muscle repair and regeneration |
| 07/10/2013 | CN103200936A Novel n-hydroxy-benzamides for the treatment of cancer |
| 07/10/2013 | CN103200935A A composition comprising s-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate and croscarmellose sodium |
| 07/10/2013 | CN103200934A Pharmaceutical composition for treating HCV infections |
| 07/10/2013 | CN103200931A Liquid pharmaceutical composition for the treatment of a posterior eye disease |
| 07/10/2013 | CN103200830A Method and preparation for the treatment or prevention of anxiety or neurogenesis |
| 07/10/2013 | CN103200827A Lipid supplements for maintaining health and the treatment of acute and chronic disorders |
| 07/10/2013 | CN103200822A 2-substituted-8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d] pyrimidine-6-carbonitriles and uses thereof |
| 07/10/2013 | CN103200821A Polymorphs of febuxostat |
| 07/10/2013 | CN103200820A Novel substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors |
| 07/10/2013 | CN103194489A Novel cationic liposome nucleic acid pharmaceutical preparation as well as preparation method and application thereof |